PL376440A1 - Pochodne pirydopirolizyny i pirydoindolizyny - Google Patents

Pochodne pirydopirolizyny i pirydoindolizyny

Info

Publication number: PL376440A1
Authority: PL; Poland
Prior art keywords: pyridopyrrolizine; pyridoindolizine; derivatives; prostaglandin; asthma
Prior art date: 2002-10-30

Application number

PL03376440A

Other languages

English (en)

Inventor

Yves Leblanc

Claude Dufresne

Patrick Roy

Original Assignee

Merck Frosst Canada Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-30

Filing date

2003-10-28

Publication date

2005-12-27

2003-10-28 Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.

2005-12-27 Publication of PL376440A1 publication Critical patent/PL376440A1/pl

Links

WBDYUBOQSGMRIY-UHFFFAOYSA-N 9h-pyrido[3,2-a]pyrrolizine Chemical compound N1=CC=CC2=C3CC=CN3C=C21 WBDYUBOQSGMRIY-UHFFFAOYSA-N 0.000 title abstract 2
QRGZLKNNVGYPQL-UHFFFAOYSA-N pyrrolo[2,1-f][1,6]naphthyridine Chemical class C12=CC=CN=C2C=CN2C1=CC=C2 QRGZLKNNVGYPQL-UHFFFAOYSA-N 0.000 title abstract 2
206010028735 Nasal congestion Diseases 0.000 abstract 1
229940122144 Prostaglandin receptor antagonist Drugs 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
150000003180 prostaglandins Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Pregnancy & Childbirth (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)

PL03376440A 2002-10-30 2003-10-28 Pochodne pirydopirolizyny i pirydoindolizyny PL376440A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42244302P	2002-10-30	2002-10-30
US48262603P	2003-06-26	2003-06-26

Publications (1)

Publication Number	Publication Date
PL376440A1 true PL376440A1 (pl)	2005-12-27

Family

ID=32233493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03376440A PL376440A1 (pl)	2002-10-30	2003-10-28	Pochodne pirydopirolizyny i pirydoindolizyny

Country Status (15)

Country	Link
US (1)	US7618979B2 (pl)
EP (1)	EP1558614B1 (pl)
JP (1)	JP4332151B2 (pl)
KR (1)	KR20050084890A (pl)
AT (1)	ATE479686T1 (pl)
AU (1)	AU2003275868B2 (pl)
BR (1)	BR0315681A (pl)
CA (1)	CA2503767C (pl)
DE (1)	DE60334015D1 (pl)
MX (1)	MXPA05004715A (pl)
NO (1)	NO20052591L (pl)
NZ (1)	NZ539406A (pl)
PL (1)	PL376440A1 (pl)
RU (1)	RU2342386C2 (pl)
WO (1)	WO2004039807A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7405210B2 (en)	2003-05-21	2008-07-29	Osi Pharmaceuticals, Inc.	Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1636224B1 (en) *	2003-05-21	2010-07-14	Prosidion Limited	Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
JP4051398B2 (ja)	2004-03-11	2008-02-20	アクテリオンファマシューティカルズリミテッド	テトラヒドロピリドインドール誘導体
GB0412914D0 (en) *	2004-06-10	2004-07-14	Oxagen Ltd	Compounds
EA200701324A1 (ru)	2004-12-23	2007-10-26	Глэксо Груп Лимитед	Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
KR101329903B1 (ko)	2004-12-27	2013-11-14	액테리온 파마슈티칼 리미티드	Ｃｒｔｈ2 수용체 길항제로서의2,3,4,9-테트라하이드로-1ｈ-카르바졸유도체
GB0500604D0 (en) *	2005-01-13	2005-02-16	Astrazeneca Ab	Novel process
EP1911759A4 (en) *	2005-07-22	2010-07-21	Shionogi & Co	AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
US7956082B2 (en)	2005-07-22	2011-06-07	Shionogi & Co., Ltd	Indole derivative having PGD2 receptor antagonist activity
JP5147401B2 (ja)	2005-09-06	2013-02-20	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
EP2316824A1 (en)	2006-08-07	2011-05-04	Actelion Pharmaceuticals Ltd.	(3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates
US8772312B2 (en) *	2007-10-10	2014-07-08	Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.	Heterocyclic compounds as CRTH2 receptor antagonists
US8067445B2 (en) *	2008-02-01	2011-11-29	Panmira Pharmaceuticals, Llc	N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2245002A4 (en) *	2008-02-01	2011-08-17	Amira Pharmaceuticals Inc	AMINOALKYLBIPHENYL ANTAGONISTS N, N 'DISUBSTITUTED FROM D2 RECEPTORS OF PROSTAGLANDIN
EP2257536A4 (en) *	2008-02-14	2011-03-23	Amira Pharmaceuticals Inc	CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8497381B2 (en) *	2008-02-25	2013-07-30	Panmira Pharmaceuticals, Llc	Antagonists of prostaglandin D2 receptors
US8426449B2 (en) *	2008-04-02	2013-04-23	Panmira Pharmaceuticals, Llc	Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110112134A1 (en) *	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
EP2300425A4 (en) *	2008-06-24	2012-03-21	Panmira Pharmaceuticals Llc	PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
MX2010014172A (es)	2008-07-03	2011-02-22	Amira Pharmaceuticals Inc	Antagonistas de receptores de prostaglandina d2.
EP2149551A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma Aktiengesellschaft	Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
WO2010031184A1 (en) *	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Azaindole derivatives as crth2 receptor antagonists
WO2010031183A1 (en) *	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Indole derivatives as crth2 receptor antagonists
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en)	2008-10-08	2013-09-03	Panmira Pharmaceuticals, Llc	Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) *	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en)	2008-11-17	2013-02-26	Panmira Pharmaceuticals, Llc	Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) *	2009-01-08	2010-07-08	Amira Pharmaceuticals, Inc.	Biomarkers of inflammation
WO2011014587A2 (en)	2009-07-31	2011-02-03	Amira Pharmaceuticals, Inc.	Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (ko) *	2009-08-05	2012-05-11	판미라 파마슈티칼스, 엘엘씨	Ｄｐ2 길항제 및 이의 용도
DE102009049662A1 (de)	2009-10-13	2011-04-14	Bayer Schering Pharma Aktiengesellschaft	2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
MX2012007927A (es)	2010-01-06	2012-08-15	Panmira Pharmaceuticals Llc	Antagonistas de dp2 y usos del mismo.
MX2012010820A (es)	2010-03-22	2012-10-10	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
WO2012139033A1 (en)	2011-04-07	2012-10-11	Nexmed Holdings, Inc.	Methods and compositions for treating raynaud's disease
WO2012140612A1 (en)	2011-04-14	2012-10-18	Actelion Pharmaceuticals Ltd	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2757883B1 (en)	2011-09-22	2021-01-13	Merck Sharp & Dohme Corp.	Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2013043518A1 (en)	2011-09-22	2013-03-28	Merck Sharp & Dohme Corp.	Imidazopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en)	2011-09-22	2016-05-31	Merck Sharp & Dohme Corp.	Pyrazolopyridyl compounds as aldosterone synthase inhibitors
US9550750B2 (en)	2012-10-05	2017-01-24	Merck Sharp & Dohme Corp.	Indoline compounds as aldosterone synthase inhibitors
PH12016501764B1 (en)	2014-03-17	2024-05-17	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2017046125A1 (en)	2015-09-15	2017-03-23	Actelion Pharmaceuticals Ltd	Crystalline forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1241660A (en) *	1984-06-25	1988-09-06	Yvan Guindon	Indole-2-alkanoic acids
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
TW197442B (pl) *	1990-02-08	1993-01-01	Pfizer
US5128364A (en) *	1991-03-28	1992-07-07	Merck Frosst Canada, Inc.	Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis
DE19510965A1 (de) *	1995-03-24	1996-09-26	Asta Medica Ag	Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
PL185107B1 (pl)	1995-06-21	2003-02-28	Shionogi & Co	Bicykliczne związki aminowe, kompozycja farmaceutyczna i jej stosowanie
BR9714016A (pt)	1996-12-13	2000-02-29	Shionogi & Co	Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos
FR2772763B1 (fr) *	1997-12-24	2004-01-23	Sod Conseils Rech Applic	Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
ES2241283T3 (es)	1998-06-03	2005-10-16	SHIONOGI & CO., LTD.	Remedios para el tratamiento del prurito que contienen antagonistas de pgd2.
DE60215000T2 (de)	2001-05-23	2007-08-09	Merck Frosst Canada & Co, Kirkland	Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten

2003
- 2003-10-28 EP EP03809672A patent/EP1558614B1/en not_active Expired - Lifetime
- 2003-10-28 KR KR1020057007434A patent/KR20050084890A/ko not_active Ceased
- 2003-10-28 MX MXPA05004715A patent/MXPA05004715A/es unknown
- 2003-10-28 US US10/532,633 patent/US7618979B2/en not_active Expired - Fee Related
- 2003-10-28 BR BR0315681-8A patent/BR0315681A/pt not_active IP Right Cessation
- 2003-10-28 WO PCT/CA2003/001658 patent/WO2004039807A1/en not_active Ceased
- 2003-10-28 NZ NZ539406A patent/NZ539406A/en unknown
- 2003-10-28 DE DE60334015T patent/DE60334015D1/de not_active Expired - Lifetime
- 2003-10-28 AT AT03809672T patent/ATE479686T1/de not_active IP Right Cessation
- 2003-10-28 AU AU2003275868A patent/AU2003275868B2/en not_active Ceased
- 2003-10-28 JP JP2005501791A patent/JP4332151B2/ja not_active Expired - Fee Related
- 2003-10-28 CA CA002503767A patent/CA2503767C/en not_active Expired - Fee Related
- 2003-10-28 PL PL03376440A patent/PL376440A1/pl not_active Application Discontinuation
- 2003-10-28 RU RU2005116254/04A patent/RU2342386C2/ru active
2005
- 2005-05-27 NO NO20052591A patent/NO20052591L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1558614A1 (en)	2005-08-03
AU2003275868A1 (en)	2004-05-25
RU2342386C2 (ru)	2008-12-27
JP2006506457A (ja)	2006-02-23
US7618979B2 (en)	2009-11-17
KR20050084890A (ko)	2005-08-29
MXPA05004715A (es)	2005-08-03
ATE479686T1 (de)	2010-09-15
AU2003275868B2 (en)	2009-07-09
CA2503767A1 (en)	2004-05-13
RU2005116254A (ru)	2006-01-20
WO2004039807A1 (en)	2004-05-13
JP4332151B2 (ja)	2009-09-16
NO20052591L (no)	2005-07-29
EP1558614B1 (en)	2010-09-01
US20050272756A1 (en)	2005-12-08
NZ539406A (en)	2007-05-31
CA2503767C (en)	2009-09-22
NO20052591D0 (no)	2005-05-27
DE60334015D1 (de)	2010-10-14
BR0315681A (pt)	2005-09-06

Legal Events

Date	Code	Title	Description
2011-05-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
DE60334015D1 (de)	2010-10-14	Pyridopyrrolizin- und pyridoindolizinderivate
DE60215000D1 (de)	2006-11-09	DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
BR0112756A (pt)	2003-06-24	Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
AU2003272285A8 (en)	2004-03-29	Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
MXPA03010134A (es)	2004-03-10	Derivados de ciclohexan-1-4-diamina sustituidos.
GB0504828D0 (en)	2005-04-13	Therapeutic agents
MY132566A (en)	2007-10-31	Benzimidazolone histamine h3 antagonists
IS2564B (is)	2009-12-15	Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
ATE399770T1 (de)	2008-07-15	Tachykininrezeptorantagonisten
AU2003242544A1 (en)	2003-12-12	New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
WO2001079169A3 (en)	2002-04-04	Prostaglandin d2 receptor antagonists
WO2002072570A3 (en)	2003-03-06	Non-imidazole compounds as histamine h3 antagonists
MX2007000036A (es)	2007-05-18	Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
WO2003006604A3 (en)	2003-10-02	Cyclic peptides as potent and selective melanocortin-4 receptor agonists
GB0426313D0 (en)	2005-01-05	Therapeutic agents
MX2007002470A (es)	2009-02-12	Fenilaminotiazoles sustituidos y su uso.
AU2001225664A1 (en)	2001-12-24	5-ht3 receptor antagonists for treatment of disorders involving airway constriction
WO2004066960A3 (en)	2004-10-21	Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
WO2004111047A3 (en)	2005-04-21	Cycloalkanepyrrolopyridines as dp receptor antagonists
AU2003258630A1 (en)	2004-03-11	Pyrimidine derivatives as selective cox-2 inhibitors
WO2005048932A3 (en)	2006-09-14	N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
WO2002069944A3 (de)	2003-10-02	Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
WO2006114666A8 (en)	2008-04-03	SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
GT200200003A (es)	2002-08-19	Antagonistas de receptores de histamina
AU2002254930A1 (en)	2002-10-03	Novel medicament compositions based on anticholinergic agents and endothelin antagonists